Detalhe da pesquisa
1.
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI).
J Infect Dis
; 226(11): 1877-1881, 2022 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35429382
2.
Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021.
Euro Surveill
; 26(46)2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794537
3.
Built Environment and SARS-CoV-2 Transmission in Long-Term Care Facilities: Cross-Sectional Survey and Data Linkage.
J Am Med Dir Assoc
; 25(2): 304-313.e11, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38065220
4.
Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI).
Open Forum Infect Dis
; 10(1): ofac694, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36713473
5.
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes.
Nat Aging
; 3(1): 93-104, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37118525
6.
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.
Lancet Healthy Longev
; 3(1): e13-e21, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34935001
7.
Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
Lancet Healthy Longev
; 3(5): e347-e355, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35531432
8.
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
Lancet Healthy Longev
; 3(7): e470-e480, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35813279
9.
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study.
Lancet Healthy Longev
; 3(7): e461-e469, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35813280
10.
Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection.
Nat Aging
; 2(6): 536-547, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37118449
11.
Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study.
Lancet Healthy Longev
; 2(6): e362-e370, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34104901
12.
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Lancet Infect Dis
; 21(11): 1529-1538, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34174193
13.
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Lancet Healthy Longev
; 2(9): e544-e553, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34430954